This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
Completed Alterity protocol ATH434-201.
Expected to benefit from treatment from treatment with ATH434, in the opinion of the Investigator.
Discontinued prior ATH434 treatment (ATH434-201) for any reason.
Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the Investigator's opinion.